Nasdaq · CIK 0001822462
FHTX Foghorn Therapeutics Inc.
Insider trading from SEC Form 4. Last filing Jun 25, 2026.
In brief
Foghorn Therapeutics Inc. (FHTX) has 38 SEC Form 4 filings on file from 18 insiders, the latest filed on Jun 25, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
18
with a Form 4 at this company
Signals
Open-market buys and sells at Foghorn Therapeutics Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
Every row filed, 43 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Douglas G. Cole director | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 24, 2026 | Scott Biller director | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 24, 2026 | Neil Gallagher director | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 24, 2026 | Michael Mendelsohn director | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 24, 2026 | Thomas J. Lynch Jr. director | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 24, 2026 | Simba Gill director | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 24, 2026 | B Lynne Parshall director | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 24, 2026 | Stuart Duty director | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 24, 2026 | Ian F Smith director | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Apr 9, 2026 | Adrian Gottschalk Chief Executive Officer | GGift Common Stockindirect: By 2023 GRAT | -47,497 | $0.00 | $0 | 0 | Apr 13, 2026 |
| Apr 9, 2026 | Adrian Gottschalk Chief Executive Officer | GGift Common Stockindirect: By Living Trust | +47,497 | $0.00 | $0 | 211,704 | Apr 13, 2026 |
| Apr 10, 2026 | Adrian Gottschalk Chief Executive Officer | GGift Common Stockindirect: 2025 GRAT | -59,208 | $0.00 | $0 | 240,792 | Apr 13, 2026 |
| Apr 10, 2026 | Adrian Gottschalk Chief Executive Officer | GGift Common Stockindirect: By Living Trust | +59,208 | $0.00 | $0 | 270,912 | Apr 13, 2026 |
| Feb 23, 2026 | Ryan D Maynard Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +400,000 | $5.75 | $2.3M | 400,000 | Feb 24, 2026 |
| Feb 5, 2026 | Adrian Gottschalk Chief Executive Officer | AGrant or award Stock option (right to buy)derivative | +1,075,000 | $5.23 | $5.6M | 1,075,000 | Feb 6, 2026 |
| Jan 30, 2026 | Steven F. Bellon Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +300,000 | $5.71 | $1.7M | 300,000 | Feb 2, 2026 |
| Jan 30, 2026 | Alfonso Quintas Cardama Chief Medical Officer | AGrant or award Stock option (right to buy)derivative | +300,000 | $5.71 | $1.7M | 300,000 | Feb 2, 2026 |
| Jan 30, 2026 | Carlos Costa Chief People Officer | AGrant or award Stock option (right to buy)derivative | +230,000 | $5.71 | $1.3M | 230,000 | Feb 2, 2026 |
| Jan 30, 2026 | Michael LaCascia Chief Legal Officer | AGrant or award Stock option (right to buy)derivative | +295,000 | $5.71 | $1.7M | 295,000 | Feb 2, 2026 |
| Jan 30, 2026 | Anna Rivkin Chief Business Officer | AGrant or award Stock option (right to buy)derivative | +165,000 | $5.71 | $942k | 165,000 | Feb 2, 2026 |
| Jan 13, 2026 | Flagship Pioneering, LLC director, owner | AGrant or award Pre-Funded Warrants to purchase Common Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | +2,235,468 | $6.71 | $15M | 2,235,468 | Jan 15, 2026 |
| Jan 13, 2026 | Flagship Pioneering, LLC director, owner | AGrant or award Series 1 Warrants to purchase Common Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | +1,117,734 | - | - | 1,117,734 | Jan 15, 2026 |
| Jan 13, 2026 | Flagship Pioneering, LLC director, owner | AGrant or award Series 2 Warrants to purchase Common Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | +1,117,734 | - | - | 1,117,734 | Jan 15, 2026 |
| Jun 17, 2025 | Scott Biller director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
| Jun 17, 2025 | Douglas G. Cole director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
| Jun 17, 2025 | Simba Gill director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
| Jun 17, 2025 | Thomas J. Lynch Jr. director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
| Jun 17, 2025 | Michael Mendelsohn director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
| Jun 17, 2025 | B Lynne Parshall director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
| Jun 17, 2025 | Ian F Smith director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
| May 1, 2025 | Stuart Duty director | AGrant or award Stock Options (Right to buy)derivative | +50,000 | $4.16 | $208k | 50,000 | May 2, 2025 |
| May 1, 2025 | Neil Gallagher director | AGrant or award Stock Options (Right to buy)derivative | +50,000 | $4.16 | $208k | 50,000 | May 2, 2025 |
| Apr 25, 2025 | Adrian Gottschalk Chief Executive Officer | GGift Common Stockindirect: See Footnote | -300,000 | $0.00 | $0 | 511,704 | Apr 28, 2025 |
| Apr 25, 2025 | Adrian Gottschalk Chief Executive Officer | GGift Common Stockindirect: See Footnote | +300,000 | $0.00 | $0 | 511,704 | Apr 28, 2025 |
| Apr 9, 2025 | Adrian Gottschalk Chief Executive Officer | GGift Common Stockindirect: See Footnote | -197,906 | $0.00 | $0 | 511,704 | Apr 10, 2025 |
| Apr 9, 2025 | Adrian Gottschalk Chief Executive Officer | GGift Common Stockindirect: See Footnote | +197,906 | $0.00 | $0 | 511,704 | Apr 10, 2025 |
| Jan 22, 2025 | Steven F. Bellon Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +140,000 | $4.37 | $612k | 140,000 | Jan 24, 2025 |
| Jan 22, 2025 | Alfonso Quintas Cardama Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +125,000 | $4.37 | $546k | 125,000 | Jan 24, 2025 |
| Jan 22, 2025 | Carlos Costa Chief People Officer | AGrant or award Stock Option (right to buy)derivative | +115,000 | $4.37 | $503k | 115,000 | Jan 24, 2025 |
| Jan 22, 2025 | Michael LaCascia Chief Legal Officer | AGrant or award Stock Option (right to buy)derivative | +126,000 | $4.37 | $551k | 126,000 | Jan 24, 2025 |
| Jan 22, 2025 | Adrian Gottschalk Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +400,000 | $4.37 | $1.7M | 400,000 | Jan 24, 2025 |
| Jan 22, 2025 | Anna Rivkin Chief Business Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $4.37 | $219k | 50,000 | Jan 24, 2025 |
| Jan 22, 2025 | Kristian Humer Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +120,000 | $4.37 | $524k | 120,000 | Jan 24, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Steven F. BellonChief Scientific Officer
- Scott Billerdirector
- Alfonso Quintas CardamaChief Medical Officer
- Douglas G. Coledirector
- Carlos CostaChief People Officer
- Stuart Dutydirector
- Flagship Pioneering, LLCdirector, owner
- Simba Gilldirector
- Adrian GottschalkChief Executive Officer
- Neil Gallagherdirector, president, officer
- Kristian HumerChief Financial Officer
- Michael LaCasciaChief Legal Officer
- Thomas J. Lynch Jr.director
- Ryan D MaynardChief Financial Officer
- Michael Mendelsohndirector
- B Lynne Parshalldirector
- Anna RivkinChief Business Officer
- Ian F Smithdirector, ceo, officer
Questions about FHTX
Answered from the filings on this page, as of the latest one.
Are insiders buying FHTX?
No. In the last 90 days no insider at Foghorn Therapeutics Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade FHTX on the open market?
No open-market trade has been scored at Foghorn Therapeutics Inc.. The latest Form 4 on file was filed on Jun 25, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Foghorn Therapeutics Inc.?
18 people have filed a Form 4 at Foghorn Therapeutics Inc., among them Steven F. Bellon (Chief Scientific Officer), Scott Biller (director), Alfonso Quintas Cardama (Chief Medical Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.